Claro Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Claro Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,149	Closed	-$304K	–	265
2021 Q2	$304K	Hold	8,149	–	–	0.14%	163
2021 Q1	$208K	Buy	+8,149	New	+$208K	0.11%	198
2020 Q3	–	Sell	-8,127	Closed	-$206K	–	204
2020 Q2	$206K	Buy	+8,127	New	+$175K	0.14%	176
2020 Q1	–	Sell	-9,829	Closed	-$217K	–	195
2019 Q4	$217K	Sell	9,829 -292	-3%	-$5.88K	0.17%	152
2019 Q3	$145K	Sell	10,121 -2,923	-22%	-$41.8K	0.13%	159
2019 Q2	$205K	Hold	13,044	–	–	0.19%	150
2019 Q1	$191K	Hold	13,044	–	–	0.19%	143
2018 Q4	$199K	Buy	+13,044	New	+$172K	0.16%	135

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Claro Advisors's DRNA Position: Q3 2021 in Review

Claro Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 8,149 shares — an estimated $304K sold.

Claro Advisors first reported a position in DRNA in Q4 2018 and held it in 8 quarters. The position peaked at $304K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Claro Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Claro Advisors sold 8,149 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $304K.
Claro Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and held it in 8 quarters.
Claro Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $304K in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Claro Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.